RenovoRx, Inc. Common Stock
$1.69
-$0.04 (-2.31%)
$1.67Day Range$1.75
Key Statistics
Market Cap
$76.27M
Shares Outstanding
45.1M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 26, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.74
Day High
$1.75
Day Low
$1.67
Volume
566.9K
VWAP
$1.70
Prev Close
$1.73
Transactions
--
Acc. Volume
--
About RenovoRx, Inc. Common Stock
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
PHARMACEUTICAL PREPARATIONSSIC 283417 employees2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040408-800-2649IPO Aug 26, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001574094
- Composite FIGI
- BBG005XWWZK6
- Share Class FIGI
- BBG005XWWZL5
- Ticker Root
- RNXT
- SIC Code
- 2834
About RenovoRx, Inc. Common Stock (RNXT) Stock
RenovoRx, Inc. Common Stock (RNXT) closed the 2026-09-18 session at $1.69, down 2.31% versus the previous close (-0.04). The stock opened at $1.74 and traded between $1.67 and $1.75 during that session. Session trading volume was 567K shares. The volume-weighted average price (VWAP) is $1.70.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
RenovoRx, Inc. Common Stock has a market capitalization of $76.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RNXT is listed on the XNAS exchange. The company employs approximately 17 people. RenovoRx, Inc. Common Stock is headquartered in MOUNTAIN VIEW, CA. The recorded listing date is 2021-08-26.
On this page you can find market RNXT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.